Compare AMPY & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMPY | CNTN |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | 184 | 12 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.9M | 185.3M |
| IPO Year | 2011 | 2022 |
| Metric | AMPY | CNTN |
|---|---|---|
| Price | $5.25 | $3.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 650.5K | 457.8K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $208,637,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.60 | $2.89 |
| 52 Week High | $6.79 | $5.27 |
| Indicator | AMPY | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 48.69 |
| Support Level | $4.98 | $3.01 |
| Resistance Level | $5.85 | $3.76 |
| Average True Range (ATR) | 0.25 | 0.25 |
| MACD | -0.06 | 0.04 |
| Stochastic Oscillator | 21.34 | 44.12 |
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The companies oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.